Pharmacokinetics in geriatric psychiatry

Current Psychiatry Reports

Volumn 10, Issue 1, 2008, Pages 30-36

  Bigos, Kristin L ^c   Chew, Marci L ^a   Bies, Robert R ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ARMODAFINIL; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DEXMETHYLPHENIDATE; ELESTRIN; ESTRADIOL; FLUPHENAZINE; LEVODOPA; LISDEXAMFETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NIRAVAM; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RAMELTEON; RISPERIDONE; RIVASTIGMINE; ROTIGOTINE; SEROQUEL XR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VARENICLINE; ZIPRASIDONE;

AGED; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GERONTOPSYCHIATRY; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MENOPAUSE RELATED DISORDER; MORNING DOSAGE; PARKINSON DISEASE; POPULATION MODEL; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; TOBACCO DEPENDENCE;

ADMINISTRATION, CUTANEOUS; AGED; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; MENTAL DISORDERS; METABOLIC CLEARANCE RATE; PSYCHOTROPIC DRUGS;

EID: 39449130457     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0007-4     Document Type: Review

References (48)

1. Mulsant BH, Pollock BG, Kirshner M, et al.: Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003, 60:198-203.
2. Gurwitz JH, Field TS, Harrold LR, et al.: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2005, 289:1107-1116.
3. Mannesse CK, Derkx FH, de Ridder MA, et al.: Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997, 315:1057-1058.
4. Sheiner LB, Steimer JL: Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000, 40:67-95.
5. Turnheim K: When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003, 38:843-853.
6. Turnheim K: Drug therapy in the elderly. Exp Gerontol 2004, 39:1731-1738.
7. Ette EI, Williams PJ: Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004, 38:1907-1915.
8. Ette EI, Williams PJ: Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004, 38:1702-1706.
9. Davidian M, Giltinan DM: Nonlinear Models for Repeated Measurement Data. Boca Raton, FL: Chapman and Hall/CRC; 1995.
10. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980, 8:553-571.
11. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981, 9:635-651.
12. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983, 11:303-319.
13. Sheiner LB: The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984, 15:153-171.
14. Bigos KL, Bies RR, Pollock BG: Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry 2006, 14:993-1003.
15. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
16. Bigos KL, Pollock BG, Coley KC, et al.: Sources of variability in olanzapine exposure from the CATIE-AD study [abstract]. Biol Psychiatry 2006, 59:140S.
17. Chew ML, Pollock BG, Coley KC, et al.: Population pharmacokinetic model of quetiapine using highly sparse data from the CATIE study [abstract]. Biol Psychiatry 2006, 59:125S.
18. Feng Y, Pollock BG, Coley KC, et al.: Assessing sources of variability in risperidone pharmacokinetics: a population analysis of risperidone using highly sparse sampling measurements from the CATIE study [abstract]. Biol Psychiatry 2006, 59:230S.
19. Bigos KL, Hariri AR: Neuroimaging: technologies at the interface of genes, brain and behavior. Neuroimaging Clin N Am 2007, 17:459-467.
20. Bigos KL, Pollock BG, Coley KC, et al.: Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, In press.
21. Bies RR, Mulsant BH, Rosen J, et al.: Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. Am J Geriatr Pharmacother 2005, 3:1-5.
22. Feng Y, Pollock BG, Ferrell RE, et al.: Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006, 61:558-569.
23. Bies RR, Bigos KL, Pollock BG: Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med 2003, 6:12-20.
24. Bies RR, Bigos KL, Pollock BG: Gender and antidepressants. In Principles of Gender-specific Medicine. Edited by Legato MJ. New York: Elsevier Academic Press; 2004:860-868.
25. Bies RR, Feng Y, Lotrich FE, et al.: Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 2004, 44:1352-1359.
26. Vermeulen A, Piotrovsky V, Ludwig EA: Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 2007, 34:183-206.
27. Nyholm D: Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006, 45:109-136.
28. Splinter MY: Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome. Ann Pharmacother 2007, 41:285-295.
29. Babic T, Boothmann B, Polivka J, et al.: Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol 2006, 29:238-242.
30. Neupro [package insert]. Monheim, Germany: Schwarz Pharma; 2006.
31. Davidson M, Emsley R, Kramer M, et al.: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130.
32. Yang LP, Plosker GL: Paliperidone extended release. CNS Drugs 2007, 21:417-427.
33. Kane J, Canas F, Kramer M, et al.: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161.
34. Invega [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2007.
35. Harsh JR, Hayduk R, Rosenberg R, et al.: The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006, 22:761-774.
36. Dinges DF, Arora S, Darwish M, Niebler GE: Pharmaco-dynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006, 22:159-167.
37. Nuvigil [package insert]. Frazer, PA: Cephalon, Inc.; 2007.
38. Niravam [package insert]. Monheim, Germany: Schwarz Pharma; 2005.
39. Citalopram hydrobromide [package insert]. Bridgewater, NJ: Biovail Pharmaceuticals, Inc.; 2005.
40. Abilify Discmelt [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2006.
41. Seroquel XR [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2007.
42. Lefèvre G, Sedek G, Huang HL, et al.: Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007, 47:471-478.
43. Winblad B, Grossberg G, Frölich L, et al.: IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007, 69:S14-S22.
44. Naunton M, Al Hadithy AF, Brouwers JR, Archer DF: Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause 2006, 13: 517-527.
45. Pollock BG, Ferrell RE, Mulsant BH, et al.: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
46. Lotrich FE, Bies RR, Smith GS, Pollock BG: Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 2006, 20:33-40.
47. Pollock BG: The pharmacokinetic imperative in late-life depression. J Clin Psychopharmacol 2005, 25:S19-S23.
48. Lotrich FE, Pollock BG: Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005, 45: 1106-1122.